权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Opposing RNAi Molecule Gradient Constructs to Repair Osteochondral Defects

相反的 RNAi 分子梯度构建修复骨软骨缺损

基本信息

批准号：
10263140
负责人：
Eben Alsberg
金额：
$ 34.12万
依托单位：
UNIVERSITY OF ILLINOIS AT CHICAGO
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-04-01 至 2023-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10263140
关键词：
Address Affect Animal Model Biochemical Biocompatible Materials Biological Assay Biomechanics Biopolymers Bone Marrow Bone Morphogenetic Proteins Cartilage Cell Transplantation Cells Charge Chondrogenesis Clinical Defect Degenerative polyarthritis Dextrans Dimensions Disease Dose Encapsulated Engineering Gel Gene Expression Gene Silencing Genes Genetic Transcription Growth Factor Histologic Human Hydrogels Injury Joints Knee Laboratories Lead Mechanics Mesenchymal Stem Cells Messenger RNA MicroRNAs Microfluidic Microchips Modeling Molecular Morphology Natural regeneration Non-Viral Vector Oryctolagus cuniculus Osteogenesis Pain Pathway interactions Patients Polyethyleneimine Process Proteins Quality of life RNA RNA Interference RNA delivery Reporter Genes Small Interfering RNA Source Stains System Technology Testing Therapeutic Tissue Engineering Tissues Transfection Work articular cartilage bone clinical translation crosslink density design disability efficacious treatment healing implantation improved in vivo knock-down microfluidic technology osteochondral repair osteochondral tissue osteogenic public health relevance recruit repaired scaffold spatiotemporal stem cell differentiation subchondral bone tissue regeneration tool

项目摘要

DESCRIPTION: The treatment of osteochondral defects (OCDs), which involve damage to both the subchondral bone and articular cartilage in the affected joint, is challenging. Such debilitating defects lead to mechanical instability, pain and worsening osteoarthritic degeneration. Current therapies fail to consistently repair and restore tissue function. Osteochondral tissue engineering technology utilizing biomaterials in combination with recruited and/or transplanted cells, and/or bioactive factors has emerged as a promising alternative approach. Human mesenchymal stem cells (hMSCs) are an attractive cell source as they can easily be isolated from bone marrow, expanded in culture without losing multipotency, and under appropriate conditions can differentiate into cells of the osteogenic and chondrogenic lineages. RNA interference (RNAi) is a powerful tool permitting inhibition of gene expression at the post-translational level by the targeted destruction of specific mRNA molecules, and has the potential to revolutionize the functional repair of damaged tissue by decreasing the expression of specific proteins that negatively impact healing processes or by altering stem cell differentiation pathways. Importantly, RNAi molecules have been identified that can promote the osteogenic and chondrogenic differentiation of hMSCs. However, effective delivery of RNAi molecules to target cells in vivo remains a significant challenge limiting its therapeutic potentia. We have engineered biopolymer hydrogels capable of locally delivering bioactive RNAi molecules with tailorable release profiles for delivery to surrounding and encapsulated cells, and these gels have been used to spatially and temporally control cell gene expression and fate. Therefore, the central hypothesis of this application is that the controlled spatial and temporal presentation of dual opposing RNAi molecule gradients in a biopolymer hydrogel will drive osteogenesis and chondrogenesis of encapsulated hMSCs in opposite directions to form osteochondral constructs that can promote the healing of OCDs. This will be addressed by the following specific aims: (1) Engineer biopolymer hydrogels with opposing concentration gradients of two different siRNAs for spatiotemporally controlled, sustained gene knockdown, (2) Deliver RNAi molecules that promote osteogenesis and chondrogenesis from biopolymer gradient hydrogels and investigate their capacity to spatially guide the osteogenic and chondrogenic differentiation of encapsulated hMSCs, (3) Develop opposing RNAi molecule gradient hydrogels with tailorable dimensions using microfluidic technology, and (4) Assess the ability of the hydrogel constructs containing hMSCs and opposing RNAi molecule gradients to drive osteogenesis and chondrogenesis in vivo upon implantation into a rabbit OCD model. This application aims to demonstrate the utility of a new tissue engineering approach for enhanced osteochondral tissue regeneration, which would have great clinical utility by improving the quality of life of patients suffering from OCDs.